For example, naproxen and low-dose ibuprofen are least likely to increase cardiovascular risk while diclofenac elevates risk even in doses available without prescription.
Researchers also found that a new NSAID, etoricoxib, has a high risk of cardiovascular events and a new study of an older drug, indomethacin, casts doubt on its continued clinical use.
Related Articles on NSAIDs:
Study: NSAID Painkillers Raise Risk of Miscarriage
https://www.beckersasc.com/pain-management/study-nsaid-painkillers-raise-risk-of-miscarriage.html
Study: NSAIDs for Pain Bring Risks to Heart Patients
https://www.beckersasc.com/pain-management/study-nsaids-for-pain-bring-risks-to-heart-patients.html
Study: NSAIDs May Blunt Effect of Antidepressants
https://www.beckersasc.com/pain-management/study-nsaids-may-blunt-effect-of-antidepressants.html
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
